Monday, November 27, 2006 7:30:00 AM PDT | VentureDeal Staff
PA - Solstice Neurosciences announced the
closing of a new round of financing totaling $85 million of both equity and
Highland Capital Management led the Series B round, with participation from
earlier investors Thomas, McNerney & Partners, Investor Growth Capital
Inc., Morgan Stanley Venture Partners, and Oxford Bioscience Partners.
The proceeds will allow the company to pursue continued development for
treatments for movement disorders and cervical dystonia.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
© VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.